In addition, other evidences suggest that lupin protein can modulate the production of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein which is correlated to atherosclerosis progression and is, therefore, a novel target for hypocholesterolaemic drugs [17,18,19,20]. The gene discussed is PCSK9; the disease is atherosclerosis.